Considering that GLUT1 is the primary glucose transporter expressed in most tumor types, including breast [146], lung [147], renal cell [148], colorectal [149], and melanoma [150], and high expression correlates with poorer prognosis of most tumor types found in the Human Protein Atlas (available from www.proteinatlas.org) [151] including breast, cervical, endometrial, ovarian, head and neck, liver, lung, pancreatic, renal, urothelial, and glioma, it is likely that part of mTOR's effect on cancer progression can be attributed to its modulation of glucose uptake and, consequently, metabolism. Here, SLC2A1 is linked to neoplasm.